These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15551673)

  • 21. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].
    Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E
    Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292
    [No Abstract]   [Full Text] [Related]  

  • 23. Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines.
    O'Neil B; Martin C; Kapron A; Flynn M; Kawamoto K; Cooney KA
    Cancer Epidemiol; 2018 Oct; 56():112-117. PubMed ID: 30130683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis.
    McCaffery K; Nickel B; Pickles K; Moynihan R; Kramer B; Barratt A; Hersch J
    BMJ Open; 2019 May; 9(5):e026960. PubMed ID: 31122983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Informed consent for patients on early recognition of prostate carcinoma is insufficient].
    Börgermann C; vom Dorp F; Rossi R; Schenck M; Luboldt HJ; Rübben H
    Urologe A; 2009 Sep; 48(9):997-8, 1000-1. PubMed ID: 19680621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer. What men want from their family physicians.
    Gray R
    Can Fam Physician; 2000 Sep; 46():1713-5, 1722-4. PubMed ID: 11013784
    [No Abstract]   [Full Text] [Related]  

  • 29. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden.
    Fridriksson J; Gunseus K; Stattin P
    Scand J Urol Nephrol; 2012 Oct; 46(5):326-31. PubMed ID: 22647143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites.
    Chan EC; Vernon SW; Ahn C; Greisinger A
    Am J Public Health; 2004 Aug; 94(8):1336-8. PubMed ID: 15284039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent.
    Wolf AM; Schorling JB
    J Gerontol A Biol Sci Med Sci; 1998 May; 53(3):M195-200. PubMed ID: 9597051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why do men refuse or attend population-based screening for prostate cancer?
    Nijs HG; Essink-Bot ML; DeKoning HJ; Kirkels WJ; Schröder FH
    J Public Health Med; 2000 Sep; 22(3):312-6. PubMed ID: 11077903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications.
    Gerard MJ; Frank-Stromborg M
    Oncol Nurs Forum; 1998 Oct; 25(9):1561-9. PubMed ID: 9802052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Standards for the punch biopsy of the prostate].
    Seitz M; Schlenker B; Gratzke C; Weidlich P; Stief CG; Reich O
    MMW Fortschr Med; 2007 Jan; 149(4):35-6. PubMed ID: 17615715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial.
    Gattellari M; Ward JE
    J Med Screen; 2003; 10(1):27-39. PubMed ID: 12790313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen screening: friend or foe?
    Linn MM; Ball RA; Maradiegue A
    Urol Nurs; 2007 Dec; 27(6):481-9; quiz 490. PubMed ID: 18217530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
    Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Informed consent for PSA testing.
    Brown V
    J Fam Pract; 1996 Sep; 43(3):234-5. PubMed ID: 8797747
    [No Abstract]   [Full Text] [Related]  

  • 40. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.